At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Trading 04-19 10:19:08 EDT
264.95
+2.20
+0.84%
High265.21Low260.68Vol426.57K
Open264.21D1 Closing262.75Amplitude1.72%
Mkt Cap142.11BTradable Cap141.70BTotal Shares536.38M
T/O112.50MT/O Rate0.08%Tradable Shares534.81M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
The Dividend Goldmine: 3 Shining Stocks With Growing Payouts
InvestorPlace  ·  19:14
The Dividend Goldmine: 3 Shining Stocks With Growing Payouts
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
Zacks  ·  04-18 20:51
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
Analyst Holds on Amgen’s Tezspire amid COPD Trial Uncertainties and Pending Competitor Comparisons
TIPRANKS  ·  04-18 12:29
Analyst Holds on Amgen’s Tezspire amid COPD Trial Uncertainties and Pending Competitor Comparisons
BRIEF-Amgen Inc Says CEO Robert Bradway's 2023 Total Compensation Was $22.6 Million Versus $21.4 Million In 2022 – SEC Filing
Reuters  ·  04-18 06:25
BRIEF-Amgen Inc Says CEO Robert Bradway's 2023 Total Compensation Was $22.6 Million Versus $21.4 Million In 2022 – SEC Filing
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights
Zacks  ·  04-18 06:00
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights
Dow Falls 100 Points On Losses For Shares Of Travelers, Intel
Dow Jones  ·  04-17 23:30
Dow Falls 100 Points On Losses For Shares Of Travelers, Intel
CVS favors Humira copycats hurting AbbVie’s market share: Evercore
seekingalpha  ·  04-17 21:26
CVS favors Humira copycats hurting AbbVie’s market share: Evercore
Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble
InvestorPlace  ·  04-17 20:00
Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
InvestorPlace  ·  04-17 20:00
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
Buy Rating on Amgen: Tezspire’s Market Potential in COPD Treatment Undervalued
TIPRANKS  ·  04-17 17:45
Buy Rating on Amgen: Tezspire’s Market Potential in COPD Treatment Undervalued
Barclays Keeps Their Sell Rating on Amgen (AMGN)
TIPRANKS  ·  04-17 15:25
Barclays Keeps Their Sell Rating on Amgen (AMGN)
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
Dow Jones  ·  04-17 07:09
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
BRIEF-Amgen Planning Underway For Phase 3 Development Of tezepelumab In COPD
Reuters  ·  04-17 05:30
BRIEF-Amgen Planning Underway For Phase 3 Development Of tezepelumab In COPD
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
PR Newswire  ·  04-17 05:26
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
InvestorPlace  ·  04-17 04:30
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
As more rare disease therapies launch, their prices are rising
seekingalpha  ·  04-17 00:22
As more rare disease therapies launch, their prices are rising
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk
seekingalpha  ·  04-16
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk
3 Stocks to Buy Low Today With High Hopes for Tomorrow
InvestorPlace  ·  04-16
3 Stocks to Buy Low Today With High Hopes for Tomorrow
Amgen: I Prefer To Chase Value And Dividends
seekingalpha  ·  04-15
Amgen: I Prefer To Chase Value And Dividends
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Notable Labs (NTBL)
TIPRANKS  ·  04-15
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Notable Labs (NTBL)

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Issue price:
--